Market revenue in 2023 | USD 34.9 million |
Market revenue in 2030 | USD 172.9 million |
Growth rate | 25.7% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.19% in 2023. Horizon Databook has segmented the Denmark cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Denmark’s biotech & pharma industry is one of most innovative markets globally. It is a leader in drug development and offers attractive business solutions for international business companies. Companies are involved in R&D collaborations and several strategic alliances with research organizations & universities for faster approval or development of products in Europe.
Denmark conducts the highest number of clinical trials per capita globally. It is one of the most R&D-intensive countries and has a large concentration of researchers. The entrepreneurial ecosystem in Denmark is the fourth-best in the world.
Furthermore, outsourcing in the Denmark pharmaceutical industry has increased in recent years. This trend is driven by the need to reduce costs, increase efficiency, and access specialized expertise & technologies.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Denmark cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account